Two major biotech conferences got underway this past weekend, and new data that was presented is already having a big impact on the stock market. Here’s a summary of what happened.
CAR-T Disappointment
Data on the CAR-T treatment developed by Novartis AG NVS 0.21% presented at the American Association for Cancer Research (AACR) Conference in Philadelphia was somewhat discouraging. Five patients undergoing CAR-T cancer treatment as part of a study on the therapy demonstrated little improvement.
However, in addition to the five unaffected patients, malignant cells surrounding the lungs of one patient were cleared during the treatment, and the study is still in the very early stages, so all hope may not yet be lost for CAR-T therapy.
Cannacord analyst John Newman called the CAR-T results “modest at best.”
CAR-T Stocks React
Novartis’ stock is trading nearly flat on the day, but the data seems to have had a greater impact on other CAR-T names.
Juno Therapeutics Inc JUNO 13.55%, Kite Pharma Inc KITE 9.81% and ZIOPHARM Oncology Inc ZIOP 8.06% are all down more than 7.5 percent following the news. Bellicum Pharmaceuticals Inc BLCM 2.83% is trading flat.
Other Biotech Names
Stocks of most of the other companies presenting at the AACR Conference are showing little reaction following the weekend sessions. Infinity Pharmaceuticals Inc INFI 0.61% is trading slightly down, while shares of Bristol-Mysers Squibb Co BMY 0.78%, Merck & Co Inc MRK 1.28% and Pharmacyclics Inc PCYC 0.34% are all up less than 2 percent on Monday.
Incyte Corp INCY 3.79% shares are showing a nice 2.7 percent gain.
No earth-shattering news appears to have come out of the American Academy of Neurology Conference this weekend, as shares of Biogen Inc BIIB 0.83%, PTC Therapeutics Inc PTCT 1.81%, Isis Pharmaceuticals Inc ISIS 0.26% and Alnylam Pharmaceuticals Inc ALNY 1.45% are all trading within 2 percent of last week’s closing prices.
Read this article and all my other articles for free on Benzinga by clicking here
Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
